CN110882254B - Composition for treating acute gastritis and application thereof - Google Patents
Composition for treating acute gastritis and application thereof Download PDFInfo
- Publication number
- CN110882254B CN110882254B CN201911120512.0A CN201911120512A CN110882254B CN 110882254 B CN110882254 B CN 110882254B CN 201911120512 A CN201911120512 A CN 201911120512A CN 110882254 B CN110882254 B CN 110882254B
- Authority
- CN
- China
- Prior art keywords
- composition
- acute gastritis
- treating acute
- dehydroevodiamine
- gastritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a composition for treating acute gastritis and application thereof, and belongs to the field of biological medicines. The composition comprises the following raw materials in parts by weight: 20-30% of berberine, 10-30% of evodiamine, 15-30% of rutaecarpine and 10-30% of dehydroevodiamine. The application of the composition in preparing a medicine for treating acute gastritis. The invention has the advantage of remarkably reducing the gastric mucosal ulcer index of mice.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to a composition for treating acute gastritis and application thereof.
Background
Acute gastritis is a digestive dysfunction and inflammatory reaction which are caused by improper diet, overeating, medicine, bile reflux, virus infection and the like, and is mainly manifested as abdominal distension, diarrhea, nausea, vomiting, fever and the like; severe cases may include hematemesis, dark feces, even loss of water, poisoning, shock, etc. Western medicines mostly treat diseases by antispasmodics, gastric mucosa protection preparations, antacids and the like. Although the symptoms of the patients are improved, the recurrence rate is higher, the long-term treatment effect is not good, and a plurality of side effects can be seen. The gastritis belongs to the category of epigastric pain in the traditional Chinese medicine, the traditional Chinese medicine has a long history of treating the gastritis, the curative effect is clinically verified, the medicine is safe and reliable, and a new channel and a new direction can be provided for the research and development of a new acute gastritis medicine derived from the traditional Chinese medicine.
The classic famous prescription ZUOJIN pill is from Danxi Xin Fa, Huo Liu, takes Coptis chinensis with effects of soothing liver, clearing liver and bitter cold as monarch drug, is supplemented with a small amount of pungent and hot fructus evodiae with pungent taste, pungent flavor and bitter taste, and is formed in opposite directions, and is mainly used for treating digestive system diseases, such as helicobacter pylori infection, peptic ulcer and the like. Based on the new trend of the research and development of the traditional Chinese medicines with the current components, the research is based on the classic theory of treating gastritis by the Zuojin pill and the long-term safe and reliable curative effect, further combines the main components berberine, evodiamine, rutaecarpine and dehydroevodiamine in the Zuojin pill for treating acute gastritis, and verifies the effectiveness of each monomer component and the composition in treating acute gastritis. So far, no record and report about the treatment of acute gastritis by the composition of berberine, evodiamine, rutaecarpine and dehydroevodiamine exists in the prior art.
Disclosure of Invention
The invention aims to disclose a composition for treating acute gastritis.
The second purpose of the invention is to disclose the application of the composition.
The purpose of the invention is realized by the following technical scheme:
the composition for treating acute gastritis comprises the following raw materials in parts by weight: 20-30% of berberine, 10-30% of evodiamine, 15-30% of rutaecarpine and 10-30% of dehydroevodiamine.
The composition of the technical scheme comprises the following raw materials in parts by weight: 25% of berberine, 20% of evodiamine, 20% of rutaecarpine and 20% of dehydroevodiamine.
The composition comprises berberine, evodiamine, rutaecarpine and dehydroevodiamine according to the mass ratio of 1:1:1: 1.
The composition of the technical scheme is applied to preparing the medicine for treating acute gastritis.
According to the application of the technical scheme, the composition can obviously reduce the gastric mucosal ulcer index of the mouse.
The application of the technical scheme is that the medicine for treating acute gastritis comprises effective dose of dehydroevodiamine and a pharmaceutically acceptable carrier.
The use according to the above technical scheme, wherein the pharmaceutically acceptable carrier is a diluent, a disintegrant, a binder, a lubricant or a stabilizer.
The use of the above technical solution, wherein the diluent is one of lactose or dextrin.
The application of the technical scheme is that the preparation form of the medicine for treating acute gastritis is one of powder, fine granules, capsules or tablets.
The invention has the following beneficial effects:
the composition can obviously reduce the gastric mucosal ulcer index of mice.
Description of the drawings:
1. FIG. 1 shows the effect of the composition of the present invention on the gastric histopathology (HE staining, 200X) in mice with acute gastritis.
The specific implementation mode is as follows:
in order to facilitate the understanding of the technical scheme of the invention, the following is a composition for treating acute gastritis and the application thereof will be further described with reference to the specific examples.
Example 1:a composition for treating acute gastritis:
weighing 20g of berberine, 30g of evodiamine, 30g of rutaecarpine and 30g of dehydroevodiamine; and then mixing the powder uniformly to obtain the composition for treating acute gastritis.
Example 2:a composition for treating acute gastritis:
weighing 25g of berberine, 20g of evodiamine and 20g of dehydroevodiamine, wherein 23g of rutaecarpine is rutaecarpine; and then mixing the powder uniformly to obtain the composition for treating acute gastritis.
Example 3:a composition for treating acute gastritis:
weighing berberine, evodiamine, rutaecarpine and dehydroevodiamine according to the weight ratio of 1:1:1:1, and mixing the above powder to obtain the composition for treating acute gastritis.
Example 4:a composition for treating acute gastritis:
weighing 20g of berberine, 20g of evodiamine and 20g of dehydroevodiamine; and then mixing the powder uniformly to obtain the composition for treating acute gastritis.
The effect of the composition for treating acute gastritis according to the present invention in treating acute gastritis is illustrated by specific experimental examples below.
The compositions used in this example were prepared as in example 4.
Experimental example 1:the treatment effect of the composition on acute gastritis is evaluated by adopting an absolute ethyl alcohol-induced mouse acute gastritis model:
the method comprises the following steps: after 1 week of acclimatization, the mice were randomly divided into 7 experimental groups (control group mice, model group mice, berberine dose group, evodiamine dose group, rutaecarpine dose group, dehydroevodiamine dose group and composition (1:1:1:1) group, each containing 10 animals, and administered once daily intragastrically for three consecutive days. Control mice received 1% CMC; model group mice received 1% CMC; the berberine dosage group is used for intragastrically administering berberine at a rate of 20mg/kg, the evodiamine dosage group is used for intragastrically administering evodiamine at a rate of 20mg/kg, the rutaecarpine dosage group is used for intragastrically administering rutaecarpine at a rate of 20mg/kg, and the dehydroevodiamine dosage group is used for intragastrically administering dehydroevodiamine at a rate of 20 mg/kg; composition (1:1:1:1) dose group the composition was administered at 20mg/kg by gavage. Prior to the experiment, mice were fasted for 12 hours but had free access to water. The mice were then treated as above, with a 0.01ml/g dose of absolute ethanol to induce acute ulcers 1 hour after the last intragastric administration, the animals were sacrificed 1 hour later, the stomach removed and opened along the maximum curve of the mouse's stomach with a 0.9% saline flush to clear the waste. The stomach is then visually inspected to detect any bleeding damage on the gastric mucosa. One observer, who did not understand the sample itself, examined gastric tissue for lesions in the gastric mucosa, which were expressed in the UI score as follows: a: congestion erythema, erosion, and bleeding points scattered are counted as 1 point; b: the number of small ulcers with a diameter of less than 1mm is 1-5, and the number is counted as 2 points; c: the number of small ulcers <1mm in diameter is more than 1-5 or obvious ulcers >1mm in diameter, counted in 3 points; d: 1 obvious ulcer with the diameter of more than 1mm, and the score is 4; e: perforated ulcer, counted as 5 points. The ulcer index was determined by summing the scores of all ulcers in each stomach. Gastric tissue was harvested at 1.0cm of the gastric gland into the pylorus and fixed in 4% paraformaldehyde solution for 24 hours. Washing was done by tap water and then dehydration in upgraded ethanol. The samples were removed in xylene and embedded in paraffin, cut to 5um and mounted on clean slides, deparaffinized and rehydrated, and then stained with hematoxylin and eosin.
Secondly, the result is:
(1) effect of the composition of interest on the gastric mucosal Ulcer Index (UI) of mice with acute gastritis:
as shown in table 1, the gastric mucosal ulcer index of the model group mice is significantly increased compared with that of the normal control group; compared with a model group, the composition and the monomer compound remarkably reduce the gastric mucosal ulcer index of the mouse, and the curative effect of the composition is more remarkable than that of each monomer compound.
TABLE 1 Effect of compositions on gastric mucosal Ulcer Index (UI) in mice with acute gastritis
Note: compared to the normal group:#P<0.01, compared to the model set,**P<0.01,*P<0.05。
(2) and the effect of the composition on the gastric histopathology of mice with acute gastritis:
as shown in figure 1, the epithelium on the surface of the stomach of the normal control group mouse is regularly arranged, the glands in the mucosa are abundant, the structure is complete, and the interstitial substances do not have vascular congestion. The gastric mucosa of the mice in the model group has the symptoms of small vessel congestion, interstitial edema bleeding, mucosa kernel and skin cell shedding, erosion, degeneration and small ulcer formation. The monomer compounds and the composition group have the advantages that the epithelial cells on the surface of the stomach are remarkably reduced in shedding and denaturation, the ulcer formation is remarkably reduced, and the curative effect of the composition is more remarkable than that of the monomer compounds.
The above examples show that the invention has significant therapeutic effect on acute gastritis induced by absolute ethyl alcohol. Therefore, the target composition can obviously inhibit the occurrence and development of acute gastritis and can be used for preparing the medicine for treating the acute gastritis.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims; meanwhile, any equivalent changes, modifications and variations of the above embodiments according to the essential technology of the present invention are within the scope of the technical solution of the present invention.
Claims (8)
1. A composition for treating acute gastritis is characterized by comprising the following raw materials: berberine, evodiamine, rutaecarpine and dehydroevodiamine according to the mass ratio of 1:1:1: 1.
2. Use of a composition according to claim 1 for the manufacture of a medicament for the treatment of acute gastritis.
3. Use according to claim 2, characterized in that: the composition can remarkably reduce gastric mucosal ulcer index of mice.
4. Use according to claim 2, characterized in that: the medicine for treating acute gastritis comprises effective dose of dehydroevodiamine and a pharmaceutically acceptable carrier.
5. Use according to claim 4, characterized in that: the pharmaceutically acceptable carrier is a diluent, a disintegrant, a binder, a lubricant or a stabilizer.
6. Use according to claim 5, wherein the diluent is one of lactose or dextrin.
7. The use of claim 2, wherein the medicament for treating acute gastritis is prepared in the form of one of powder, fine granules, capsules or tablets.
8. The use according to any one of claims 3 to 6, wherein the preparation of the medicament for treating acute gastritis is in the form of one of powder, fine granules, capsules or tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911120512.0A CN110882254B (en) | 2019-11-15 | 2019-11-15 | Composition for treating acute gastritis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911120512.0A CN110882254B (en) | 2019-11-15 | 2019-11-15 | Composition for treating acute gastritis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110882254A CN110882254A (en) | 2020-03-17 |
| CN110882254B true CN110882254B (en) | 2021-05-11 |
Family
ID=69747654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911120512.0A Expired - Fee Related CN110882254B (en) | 2019-11-15 | 2019-11-15 | Composition for treating acute gastritis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110882254B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114404420A (en) * | 2021-10-28 | 2022-04-29 | 北京大学 | Application of traditional Chinese medicine monomer composition in preventing and/or treating alcoholic gastric injury |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014047779A1 (en) * | 2012-09-25 | 2014-04-03 | 鼎泓国际投资（香港）有限公司 | Pharmaceutical composition containing evodiamine and evodiamine derivative and bcl-2 inhibitor and use thereof |
-
2019
- 2019-11-15 CN CN201911120512.0A patent/CN110882254B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014047779A1 (en) * | 2012-09-25 | 2014-04-03 | 鼎泓国际投资（香港）有限公司 | Pharmaceutical composition containing evodiamine and evodiamine derivative and bcl-2 inhibitor and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| "左金丸临床应用与实验研究进展";褚璨灿等;《实用中医药杂志》;20190531;第35卷(第5期);第626-629页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110882254A (en) | 2020-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sanati et al. | A review of the effects of Capsicum annuum L. and its constituent, capsaicin, in metabolic syndrome | |
| CN113288978A (en) | Composition for treating gout and preparation method and application thereof | |
| WO2021017434A1 (en) | Application of acanthopanax trifoliatus polysaccharide atp1-1 in preparation of medicines for treating diabetes | |
| CN110882254B (en) | Composition for treating acute gastritis and application thereof | |
| WO2015077977A1 (en) | Traditional chinese medicine composition for treating ulcerative colitis, and preparation method thereof | |
| CN114177264A (en) | Traditional Chinese medicine composition for treating diabetes and nephritis and preparation method and application thereof | |
| WO2021213230A1 (en) | Application of traditional chinese medicine composition in preparation of drug for treating or preventing fatty liver disease | |
| CN1286521C (en) | Medication for treating ulcer disease, gastritis, stomachache, abdominal pain | |
| Sharma et al. | Ethnopharmacological importance of Asparagus racemosus: A review | |
| CN115463201A (en) | Traditional Chinese medicine composition capable of preventing intestinal inflammation and cancer transformation and preparation method and application thereof | |
| CN112076249B (en) | Application of perilla leaf extract in preparing medicament for treating inflammatory bowel disease | |
| CN110917198B (en) | Application of dehydroevodiamine in preparation of medicine for treating acute gastritis | |
| CN103446387B (en) | Traditional Chinese medicine composition for treating hyperthyroidism and preparation method thereof | |
| CN101104024A (en) | Traditional Chinese medicine composition for treating benign prostate hyperplasia and application thereof | |
| WO2004084924A1 (en) | Pharmaceutical composition for treatment of bph and preparation thereof | |
| CN115715782B (en) | Traditional Chinese medicine composition for preventing and treating ulcerative colitis and application thereof | |
| CN1041992C (en) | Preparation technology of cold resistant panacla tablet | |
| CN117323402B (en) | Pharmaceutical composition for treating enteritis and preparation method thereof | |
| CN113425713B (en) | Pharmaceutical composition for treating duodenal ulcer | |
| CN101991678B (en) | Application of India madder root in preparing medicine for preventing and treating kidney disease | |
| CN101199574A (en) | Function of extract of boraginaceae cynoglossum furcatum class plant in preparing anti-inflammation analgesis medicament | |
| WO2015100579A1 (en) | Pharmaceutical composition for treating acquired immune deficiency syndrome and method for preparing same | |
| CN113599484A (en) | Traditional Chinese medicine composition for treating pain and preparation method and application thereof | |
| CN104689246B (en) | A kind of medicine for the treatment of gastric cancer | |
| CN117919316A (en) | Multi-target point total-cause traditional Chinese medicine compound composition for prostate cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210511 Termination date: 20211115 |